These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. Koenig W Int J Cardiol; 2013 Oct; 168(6):5126-34. PubMed ID: 23978367 [TBL] [Abstract][Full Text] [Related]
4. Atorvastatin Reduces Plasma Inflammatory and Oxidant Biomarkers in Patients With Risk of Atherosclerotic Cardiovascular Disease. Mayyas F; Baydoun D; Ibdah R; Ibrahim K J Cardiovasc Pharmacol Ther; 2018 May; 23(3):216-225. PubMed ID: 29343081 [TBL] [Abstract][Full Text] [Related]
5. Usefulness of Lipoprotein-Associated Phospholipase A Tibuakuu M; Kianoush S; DeFilippis AP; McEvoy JW; Zhao D; Guallar E; Ballantyne CM; Hoogeveen RC; Blaha MJ; Michos ED Am J Cardiol; 2018 May; 121(9):1056-1064. PubMed ID: 29525060 [TBL] [Abstract][Full Text] [Related]
6. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid. Chapman MJ; Zamorano JL; Parhofer KG Pharmacol Ther; 2022 Sep; 237():108172. PubMed ID: 35304222 [TBL] [Abstract][Full Text] [Related]
7. Critical appraisal of inflammatory markers in cardiovascular risk stratification. Krintus M; Kozinski M; Kubica J; Sypniewska G Crit Rev Clin Lab Sci; 2014 Oct; 51(5):263-79. PubMed ID: 24918900 [TBL] [Abstract][Full Text] [Related]
8. Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives. Wu MF; Xu KZ; Guo YG; Yu J; Wu Y; Lin LM Cardiovasc Drugs Ther; 2019 Dec; 33(6):739-748. PubMed ID: 31655942 [TBL] [Abstract][Full Text] [Related]
9. High-Sensitivity C-Reactive Protein Discordance With Atherogenic Lipid Measures and Incidence of Atherosclerotic Cardiovascular Disease in Primary Prevention: The ARIC Study. Quispe R; Michos ED; Martin SS; Puri R; Toth PP; Al Suwaidi J; Banach M; Virani SS; Blumenthal RS; Jones SR; Elshazly MB J Am Heart Assoc; 2020 Feb; 9(3):e013600. PubMed ID: 32013698 [TBL] [Abstract][Full Text] [Related]
10. Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation. Hoogeveen RC; Ballantyne CM Clin Chem; 2021 Jan; 67(1):143-153. PubMed ID: 33257928 [TBL] [Abstract][Full Text] [Related]
11. [Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?]. Sertić J; Skorić B; Lovrić J; Bozina T; Reiner Z Acta Med Croatica; 2010 Oct; 64(4):237-45. PubMed ID: 21688606 [TBL] [Abstract][Full Text] [Related]
12. PCSK9 inhibition and inflammation: A narrative review. Ruscica M; Tokgözoğlu L; Corsini A; Sirtori CR Atherosclerosis; 2019 Sep; 288():146-155. PubMed ID: 31404822 [TBL] [Abstract][Full Text] [Related]
13. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. Jellinger PS; Handelsman Y; Rosenblit PD; Bloomgarden ZT; Fonseca VA; Garber AJ; Grunberger G; Guerin CK; Bell DSH; Mechanick JI; Pessah-Pollack R; Wyne K; Smith D; Brinton EA; Fazio S; Davidson M Endocr Pract; 2017 Apr; 23(Suppl 2):1-87. PubMed ID: 28437620 [TBL] [Abstract][Full Text] [Related]
14. Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options. Berman AN; Blankstein R Curr Cardiol Rep; 2019 Aug; 21(9):110. PubMed ID: 31378838 [TBL] [Abstract][Full Text] [Related]
15. The incremental value of lipids and inflammatory biomarkers in determining residual cardiovascular risk. Mangalmurti SS; Davidson MH Curr Atheroscler Rep; 2011 Oct; 13(5):373-80. PubMed ID: 21773803 [TBL] [Abstract][Full Text] [Related]
16. Atherosclerotic cardiovascular disease risk assessment: An American Society for Preventive Cardiology clinical practice statement. Wong ND; Budoff MJ; Ferdinand K; Graham IM; Michos ED; Reddy T; Shapiro MD; Toth PP Am J Prev Cardiol; 2022 Jun; 10():100335. PubMed ID: 35342890 [TBL] [Abstract][Full Text] [Related]
17. High-Risk Atherosclerosis and Metabolic Phenotype: The Roles of Ectopic Adiposity, Atherogenic Dyslipidemia, and Inflammation. Lechner K; McKenzie AL; Kränkel N; Von Schacky C; Worm N; Nixdorff U; Lechner B; Scherr J; Weingärtner O; Krauss RM Metab Syndr Relat Disord; 2020 May; 18(4):176-185. PubMed ID: 32119801 [TBL] [Abstract][Full Text] [Related]
18. Nutrition Intervention for Reduction of Cardiovascular Risk in African Americans Using the 2019 American College of Cardiology/American Heart Association Primary Prevention Guidelines. Williams KA; Fughhi I; Fugar S; Mazur M; Gates S; Sawyer S; Patel H; Chambers D; McDaniel R; Reiser JR; Mason T Nutrients; 2021 Sep; 13(10):. PubMed ID: 34684423 [TBL] [Abstract][Full Text] [Related]
19. High-Sensitivity C-Reactive Protein Modifies the Cardiovascular Risk of Lipoprotein(a): Multi-Ethnic Study of Atherosclerosis. Zhang W; Speiser JL; Ye F; Tsai MY; Cainzos-Achirica M; Nasir K; Herrington DM; Shapiro MD J Am Coll Cardiol; 2021 Sep; 78(11):1083-1094. PubMed ID: 34503676 [TBL] [Abstract][Full Text] [Related]
20. Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines. Steen DL; Khan I; Ansell D; Sanchez RJ; Ray KK BMJ Open; 2017 Feb; 7(2):e013255. PubMed ID: 28213597 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]